Logo

QNCX

Quince Therapeutics, Inc.

QNCX

Quince Therapeutics, Inc. • NASDAQ
$3.65 ▲ 5.80% (+0.20)
Market Cap $203.24 M
52w High $3.73
52w Low $0.72
Dividend Yield 0%
P/E -3.04
Volume 760.50K
Outstanding Shares 55.68M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $11.328M ▲ $-13.442M ▲ 0% $-0.25 ▲ $-13.452M ▲
Q2-2025 $0 $9.86M ▼ $-16.049M ▼ 0% $-0.34 $-15.947M ▼
Q1-2025 $0 $14.858M ▲ $-15.03M ▼ 0% $-0.34 ▼ $-12.902M ▼
Q4-2024 $0 $10.093M ▲ $-12.458M ▼ 0% $-0.28 ▼ $-12.435M ▼
Q3-2024 $0 $5.863M $-5.492M 0% $-0.13 $-8.46M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $26.288M ▼ $109.899M ▼ $108.84M ▲ $1.059M ▼
Q2-2025 $34.708M ▲ $117.21M ▲ $105.474M ▲ $11.736M ▼
Q1-2025 $31.599M ▼ $107.089M ▼ $88.508M ▲ $18.581M ▼
Q4-2024 $40.784M ▼ $114.478M ▼ $84.332M ▲ $30.146M ▼
Q3-2024 $47.847M $126.519M $81.587M $44.932M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-13.442M ▲ $-9.928M ▲ $-1.781M ▼ $1.376M ▼ $-10.374M ▼ $-10.002M ▲
Q2-2025 $-16.049M ▼ $-11.415M ▼ $6.039M ▼ $14.412M ▲ $9.055M ▲ $-11.541M ▼
Q1-2025 $-15.03M ▼ $-9.601M ▼ $10.898M ▲ $87K ▲ $1.559M ▼ $-9.749M ▼
Q4-2024 $-12.458M ▼ $-7.552M ▼ $10.867M ▲ $0 ▲ $3.537M ▲ $-7.685M ▼
Q3-2024 $-5.492M $-7.26M $7.105M $-5M $-5.215M $-7.306M

Five-Year Company Overview

Income Statement

Income Statement Quince is still a pure R&D-stage biotech with no product revenue yet. The income statement is driven entirely by research, development, and overhead costs, which lead to recurring losses every year. Those losses have been relatively stable to slightly narrowing over time, suggesting some cost discipline, but the core picture is unchanged: the company is spending on development without any commercial offset so far. Earnings per share remain negative, reflecting this pre-revenue status and the high cost of advancing a late‑stage rare‑disease program.

Balance Sheet

Balance Sheet The balance sheet is small and fairly simple. Total assets are modest and largely made up of cash and equivalents, which have trended down as the company funds operations. Debt is very limited, so the capital structure is relatively clean, but shareholder equity has also been eroded by ongoing losses. Overall, the company has a light asset base, little leverage, and a gradual drawdown of its financial cushion, which heightens the importance of future fundraising or partnership deals to support its clinical plans.

Cash Flow

Cash Flow Cash flow is consistently negative because the business is not generating revenue and is spending on research and corporate costs. Operating cash outflows are steady rather than explosive, indicating some control over the burn rate, and capital spending needs are minimal. Still, the company is clearly reliant on external capital—equity raises, potential upfront payments from partnerships, or other financing—to continue funding its clinical trials and broader strategy. The main financial risk is how long current cash lasts and on what terms new funding can be secured.

Competitive Edge

Competitive Edge Quince operates in a very specialized niche: rare, debilitating diseases with little or no approved treatment. That gives it a potentially favorable competitive position if its lead program succeeds, as it could become the first approved therapy in its core indication and benefit from orphan drug incentives and market exclusivity. Its proprietary red‑blood‑cell drug delivery platform adds a layer of differentiation that is not easy to copy quickly. However, it is a small company with a concentrated pipeline, which makes it vulnerable to clinical setbacks and to larger competitors that might later target the same diseases if the market proves attractive.

Innovation and R&D

Innovation and R&D The company’s value is centered on innovation rather than current sales. Its flagship AIDE technology uses a patient’s own red blood cells to deliver drugs in a more targeted and potentially safer way, with the lead program aimed at a severe rare disease with no approved therapies. This is a clear example of high scientific ambition with meaningful potential patient impact. Quince is also trying to be disciplined by focusing resources on this platform, while seeking partners or out‑licensing for its bone‑targeting assets. The upside of this approach is focus and differentiation; the downside is high binary risk around a few key trials and the need for steady funding to see them through.

Summary

Quince is an early‑stage, high‑risk biotechnology company: no revenue, recurring losses, and a dependence on external capital, but with a focused and differentiated scientific strategy in rare diseases. Financially, it runs a lean, pre‑commercial model with controlled but persistent cash burn and a shrinking cash cushion. Strategically, its strength lies in a novel drug delivery platform and the potential to be first to market in a severe, underserved condition, supported by orphan drug protections and patent coverage. The company’s future trajectory hinges heavily on clinical trial outcomes and its ability to secure additional funding or partnerships, so uncertainty is high and outcomes could be very asymmetrical—either strongly positive or sharply negative depending on these key events.

NEWS

November 24, 2025 · 8:00 AM UTC

Quince Therapeutics to Participate at Investor Events in December 2025

Read more

November 12, 2025 · 4:05 PM UTC

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Read more

November 10, 2025 · 4:05 PM UTC

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Read more

October 9, 2025 · 4:05 PM UTC

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

Read more

September 25, 2025 · 4:05 PM UTC

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

Read more